A Study to Evaluate IMC-002 in Neuromyelitis Optica Spectrum Disorder (NMOSD) Patients

Clinical trial NCT06557174 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06557174
Sponsor: ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Neuromyelitis Optica Spectrum Disorder (NMOSD)

Start date: 2024-10-10
Primary completion: 2025-11-10
Enrollment: 116

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.